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 Abstract 
Objective: Insulin detemir lacks the usual propensity for insulin to cause weight gain. 
We investigated whether this effect was due to reduced energy intake and/or increased 
energy expenditure. 
Research, Design and Methods: A 32 week, randomized crossover design trial was 
undertaken in 23 patients with type 1 diabetes. Patients on a basal-bolus regime (with 
insulin aspart as bolus insulin) were randomized to insulin detemir or NPH insulin as 
basal insulin for 16 weeks, followed by the other basal insulin for 16 weeks. At the 
end of each 16 weeks, total energy expenditure (TEE), resting EE, diet induced 
thermogenesis, activity EE, energy intake, weight change, glycemic control, 
hypoglycemic episodes and hormones that affect satiety/fuel partitioning were 
measured.  
Results: After 16 weeks weight change was -0.69 ± 1.85 kg with insulin detemir and 
+1.7 ± 2.46 kg with NPH insulin (p<0.001). Total energy intake was significantly less 
with insulin detemir (2016± 501 kcal/day) than NPH insulin (2181± 559 kcal/day) 
(p=0.026). There was no significant difference in any measure of EE, %HbA1c or 
number of hypoglycemic episodes. Leptin was lower and resistin was higher with 
insulin detemir compared to NPH insulin (p=0.039, p=0.047). Following the meal, 
ghrelin and pancreatic polypeptide (p=0.002, p=0.001) were higher with insulin 
detemir. 
Conclusions: The reduced weight gain with insulin detemir compared to NPH insulin 
is due to reduced energy intake rather than increased energy expenditure. This may be 
mediated by a direct or indirect effect of insulin detemir on hormones that control 
satiety. 
 Introduction 
Exogenous insulin replacement therapy remains the most effective treatment for 
hyperglycemia in type 1 diabetes and poorly controlled type 2 diabetes patients, but it 
regularly results in excessive weight gain. The Diabetes Control and Complications 
trial (DCCT) showed that insulin-associated weight gain (1) was greater in patients 
receiving intensified intervention than that of conventional intervention (5.1 vs. 3.7 kg, 
p<0.0001 during first 12 months of therapy).  
 
In type 1 diabetes, adherence to prescribed insulin regimens may be compromised by 
a desire to avoid weight gain. The problem of insulin omission was confirmed in a 
UK study of 65 young subjects with type 1 diabetes (2). Thirty precent of the women 
admitted to having under-dosed insulin to manipulate their weight, while 45% of 
women who developed microvascular complications had intentionally misused insulin 
to prevent weight gain.   
 
Not all types of insulin treatment are equally prone to causing weight gain. Treatment 
with insulin detemir, a novel basal insulin analog, has been consistently shown to 
cause no weight gain in patients with type 1 diabetes compared to NPH insulin (3) 
and lower weight gain in type 2 diabetes.  A myristic fatty acid chain attached to the B 
terminal of the insulin molecule, allows reversible albumin binding and prolonged 
residence time in the subcutaneous depot and in the circulation (4).  
 
The mechanism(s) underlying the apparent weight advantage of insulin detemir has 
not been identified. Elucidation of this mechanism(s) could provide valuable insights 
into the ways in which insulin treatment causes weight gain in diabetes. Such 
knowledge might also enable the future development of insulin analogs with even 
greater metabolic advantages.  
 
 
 
 
 
 
RESEARCH DESIGN AND METHODS 
This study was registered with ClinicalTrials.gov (NCT00509925) and was approved 
by the UK Medicines and Healthcare Products Regulatory Agency (Eudract 2006-
003060-59), the East Kent Research Ethics Committee and University of Surrey 
Research Ethics Committee. The study was a 32 week, single-centre, open-labeled, 
randomized, cross-over trial. Twenty three patients with type 1 diabetes on a basal-
bolus regime were recruited [male: female 14:9, average age 38.8±2.17 years (mean 
±SEM), average weight 81.9±2.21 kg, body mass index 28±3.6 kg/m2, duration of 
diabetes 19.95±2.09 years, Hba1c 8.2±0.22 %]. One patient did not complete the trial 
for personal reasons. Patients were randomized to receive either insulin detemir or 
Neutral Protamine Hagedorn (NPH) insulin as basal insulin. Following 16 weeks of 
treatment, subjects were switched to the other basal insulin. Insulin aspart was used 
throughout as the bolus insulin. Both insulin detemir and NPH insulin were 
administered once or twice daily according to individual needs, according to pre-
breakfast and pre-dinner glucose targets (aiming for <6.0 mmol/l without significant 
hypoglycemia). There were 5 patients on twice daily insulin detemir and 17 patients 
on once daily insulin detemir. During the trial, subjects attended the hospital for 8 
planned visits and the investigator was in contact by telephone at least ten times. 
Inclusion criteria was type 1 diabetes>12 months, on a basal bolus insulin regimen for 
>3 months, age>18 years, BMI<40, HbA1c between 7.0 and 11.0%. Exclusion criteria 
included anticipated change in medications known to interfere with glucose 
metabolism, proliferative retinopathy, recurrent major hypoglycemia or hypoglycemic 
unawareness, impaired hepatic or renal functions, pregnancy and uncontrolled 
hypertension.  Body weight, fat mass and fat free mass (measured on a Tanita BC-418 
segmental body composition analyzer), insulin doses, hypoglycemic episodes and 
home blood glucose readings were recorded at baseline and weeks 8, 14 and 16 of 
each 16 week treatment period. During week 14 of both treatment periods, patients 
attended after an overnight fast. Resting EE (REE) for 30 minutes was measured by 
indirect calorimetry (Medgraphics CCM Express). A fasting blood sample was taken 
for the measurement of hormone/adipokines. A fasting urine sample was collected for 
baseline urine enrichment for the calculation of TEE using double labeled water. 
Subjects were then given a standard fiber-free liquid mixed meal (600 Kcal, 60 g 
carbohydrate, 21 g lipid, 19 g protein) and multiple measurements of energy 
expenditure were made by indirect calorimetry and hormonal responses measured for 
3 hours. Blood samples were taken at over 180 minutes for GLP-1, ghrelin, pancreatic 
polypeptide and peptide YY.  
 
Double labeled water (0.174 g/kg body weight 18O and 0.07 g/kg body weight 2H2O) 
was then administered orally, to measure TEE. Patients were provided with urine 
collection bottles and a log sheet to monitor the time/date of collections for 14 days. 
To measure appetite subjects were provided with a large container of a standardized 
pasta meal (1230 gm, 1740 kcal) and were asked to eat until they felt comfortably full. 
The meal was weighed before and after patients had eaten and the calorie intake 
calculated. At the end of the visit an Actiheart monitor (CamNtech Ltd, Cambridge, 
UK) was fitted to record their activity EE (AEE) for the next 5 days. Patients were 
also provided with a diary to record 7 day food intake during the following week.  
They were taught how to accurately complete a record of everything they ate.  During 
week 16 of each treatment period patients attended the hospital with their food diaries, 
Actihearts and 14 day urine samples. 
 
 Analytical Methods 
For measurement of TEE, the urine samples were analysed in duplicate for H218O and 
2H2O on a Delta plus XP isotope ratio mass spectrometer (Thermo Scientific, Bremen 
Germany) with a Gasbench II inlet system and a GCpal auto sampler (CTC analytics, 
Presearch Ltd Basingstoke, UK). 2H2 enrichment was measured using a platinum 
catalyst rod. The sample tubes were capped and flushed (100ml/min) with the 
equilibration gas, 5% H2 in helium, and incubated for a minimum of 40 mins at 
22.5oC. The isotopic enrichment of 18O was determined from carbon dioxide 
equilibration. Sample tubes were flushed with 0.5%CO2 in helium and incubated 
overnight at 22.5oC. Isotopic enrichments were measured relative to laboratory 
standards previously calibrated against international standards Vienna Standard Mean 
Ocean Water and Standard Light Arctic Precipitation (International Atomic Energy 
Agency, Vienna, Austria).. 
 
Plasma adiponectin, leptin and total ghrelin, total peptide YY (PYY) and glucagon-
like peptide-1 (GLP-1) concentrations were determined by radioimmunoassay 
(Millipore Corporate Headquarters, Billerica, MA).  Plasma IGF-1 concentration was 
determined using a non extraction immunoradiometric assay (IRMA) (Beckman 
Coulter UK Ltd, High Wycombe, UK).  Plasma resistin and pancreatic polypeptide 
were measured using an enzyme linked immunosorbant assay (ELISA) (Millipore 
Corporate Headquarters, Billerica, MA). 
 
Data analysis  
Average 24 hour total energy intake was calculated from the food diary assessment by 
a fully qualified dietician, who was blinded to which basal insulin the patient was 
taking. Diet induced thermogenesis (DIT) was calculated as area under the energy 
expenditure curve (3 hours) during the standard meal and converted to daily DIT 
using the total daily calorie intake from the food diary. 
The 18O and 2H elimination rates (kO and kH) were determined from the slope of the  
 
natural logarithm of isotope enrichment as a function of time calculated by linear  
 
regression. Total body water (TBW) was calculated as the average of the dilution  
 
space for H218O corrected by 1.01 and 2H2O corrected by 1.04. Total daily CO2  
 
production rate (rCO2) was calculated as rCO2=0.4554TBW (1.01 kO -1.04 kH). TEE  
 
was calculated from rCO2 and RQ using the equation of de Weir (5). The  
 
jackknife technique was used to correct for bias and to evaluate experimental and  
 
analytical error. TEE could only be calculated in 17 paired samples due to insufficient  
 
urine sample collection in 5 patients. 
 
The Actiheart data was downloaded at the end of each 5 day period and AEE 
calculated using a branched chain equation model (6,7). For postprandial hormone 
measurements the areas under the hormone time curves were calculated using the 
trapezoidal rule and corrected for baseline concentration. 
 
Statistical analysis 
 
Results are presented as means±SEM. The primary analysis was a comparison of the 
insulin detemir and the NPH insulin treatments, with respect to total energy 
expenditure (including components of energy expenditure, hormones, body 
composition) and separately with respect to 7-day food intake. In each case the data 
were analysed with a general linear mixed model, with subject as random effect and 
study period as well as treatment as fixed effects, including a treatment by study 
period fixed effect interaction. For the comparison of the same 2 treatments, using the 
hormone response to a meal, measured at several time points on each subject in each 
of the 2 periods, the above analysis was modified to include additionally a repeated 
measure effect for the times of measurement. The software used for these analyses 
was the PROC MIXED procedure of the SAS® statistical analysis package version 
9.1 (SAS Institute, Cary, North Carolina, USA).  Structural equation modelling was 
also performed, using SAS® PROC CALIS, to explore the relationships between food, 
and weight and the hormones measured in the study. 
RESULTS 
Body Weight (Table1) 
After 16 weeks of treatment mean body weight (Fig 1)and fat free mass was 
significantly lower with insulin detemir than with NPH insulin (p=0.0006; p=0.0001). 
Fat mass was not significantly different between treatments. 
 
Glycaemic control 
HbA1c at end of 16 weeks of treatment was not different between the two treatments 
(Table 1). Statistical analysis showed that glycaemic control during the two treatments 
could not explain the significant difference in weight (p=0.617). There was no 
significant difference in the number of hypoglycaemic episodes (<3.1 mmol/l) 
between the two treatments. There were no major hypoglycaemic episodes (defined as 
patients unable to treat themselves) in the trial.  
 
Insulin requirements 
The total daily dose of insulin aspart did not significantly change in the insulin 
detemir arm compared to NPH arm (35.8±3.66 vs 34.3±3.11 IU/day, p=0.32). The 
total daily dose of basal insulin did not significantly change with insulin detemir arm 
compared with NPH arm (27.9±3.2 vs 26.7±2.76 IU/day, p=0.33) 
 
Energy Intake and Expenditure (Table 1) 
Average daily intake measured using a 7 day food diary, was significantly lower with 
detemir compared to NPH insulin (p=0.026). This was due to lower fat (p=0.006) and 
protein intake (p=0.01), with no difference in carbohydrate intake. Calorie intake 
during the unlimited meal was not different between detemir and NPH insulin.  
 TEE, AEE, REE and DIT were not significantly different between insulin detemir and 
NPH insulin (Table 1). REE was negatively related to HbA1c (p=0.023).   
 
 
 
Hormone responses (Table 2) 
Fasting plasma leptin was lower and resistin was higher with insulin detemir than 
NPH insulin (p=0.039, p=0.047). There was no significant difference in fasting 
adiponectin and IGF-1. In response to a standard meal ghrelin and pancreatic 
polypeptide were higher with insulin detemir than with NPH insulin (p=0.002 
p=0.001). There was no significant difference in GLP-1 and Peptide YY levels.  
 
Structured equational modelling (figure 2) 
The model showed a positive relationship between weight and leptin, between weight 
and FFM, and between weight and pancreatic polypeptide. Additional negative 
relationships were observed between food intake and leptin, between resistin and 
leptin, between pancreatic polypeptide and fat free mass, and between ghrelin and fat 
free mass.  
 
DISCUSSION 
The present study is consistent with previous studies that showed treatment with 
insulin detemir to be associated with less weight gain than NPH insulin. There was a 
significant difference in energy intake as assessed by 7 day food diary. This 
corresponded to approximately 160 kcal/day difference between detemir and NPH 
insulin and could explain the observed weight difference between treatments during 
this study.  Total energy expenditure as well as its components showed no differences 
between insulin detemir and NPH insulin. It is widely recognized that energy 
expenditure decreases with weight loss. Although the average difference in weight 
between treatments at the end of the two interventions was approximately 2.4 kg, TEE  
was not different. Thus a small effect of detemir on TEE cannot be excluded. Thus 
insulin detemir appears to mediate its weight sparing effects by altering energy intake 
rather than energy expenditure.   
 
It is well recognized that in patients with diabetes (8), there is a significant 
underestimation of self-reported food intake and this was also the case in this study. 
However as this was a crossover study this would be expected to be similar with both 
insulins.  Macronutrient composition analysis showed the decrease in food intake was 
due to a significant reduction in protein and fat intake. It is notable that a decrease in 
protein intake was also noted in a study investigating the acute effects of insulin 
detemir on food intake (9).  
 
Various hypotheses have been put forward to explain the weight sparing effects of 
insulin detemir. Treatment with insulin detemir has been shown to be associated with 
reduced blood glucose variability and a reduced risk of hypoglycemia compared to 
NPH insulin (10). This might imply that patients are avoiding weight gain by reducing 
their ‘defensive snacking’. The basal analog insulin glargine has consistently reduced 
hypoglycemia compared with NPH insulin, but most trials that have reported weight 
data do not show reduced weight gain with this analog (11,12).  In the current study 
additional statistical analysis showed that the weight difference could not be 
explained by a difference in glycaemic control or hypoglycemic episodes.   
 
Another putative mechanism for the weight lowering effect of insulin detemir 
concerns the blood glucose lowering action of this analog (13). A relatively greater 
percentage of the total blood glucose lowering effect of insulin detemir is derived 
from its hepatic action, compared to that of exogenous human insulin delivered into 
the subcutaneous and systemic circulation(14,15). This could result in a relative 
reduction of peripheral lipogenesis preventing weight gain (14). It has been suggested 
that the reversible albumin-binding property of insulin detemir limits access to 
peripheral tissues through the endothelial barrier, while allowing full access to 
hepatocytes via the large sinusoidal fenestrae in hepatic capillary membranes.  The 
slight hepatoselective effect seen with insulin detemir may thus reduce free fatty acid 
deposition and glucose uptake into peripheral tissues. It has been demonstrated that 
the partitioning of fuels among different tissues and between metabolic pathways has 
significant effects on food intake (16). This may be via ATP production or may be 
due to changes in satiety factors such as leptin and ghrelin. Although there was a 
decrease in fasting leptin, an increase in resistin and an increase in the ghrelin 
response to a meal, these changes could be a consequence rather than a cause of 
weight loss (17).  In humans an infusion of PP was shown to reduce acute food intake 
at a buffet meal 2 h after the infusion and reduce food intake for the following 24 h 
[18]. PP binding sites have been demonstrated in the area postrema and the activation 
of neurons in the area postrema after PP administration suggests that PP has a central 
effect on satiety [19].The observed increase of PP in the insulin detemir treated 
patients is of considerable interest and the mechanism is unknown. 
 
An alternative mechanism that has been proposed is that insulin detemir may act 
directly on the brain to affect appetite. Insulin receptors are abundant in parts of the 
brain, including the hypothalamus (20), where insulin is involved in the regulation of 
satiety and appetite (21). Preliminary studies have reported that the effect of human 
insulin on cerebrocortical activity is compromised in obese patients, while the effect 
of insulin detemir is enhanced. Insulin detemir may have a tissue-selective action, 
with a relative preference for brain compared with peripheral tissues [22, 23].  A 
recent study [9] showed that while inducing comparable peripheral effects, insulin 
detemir had an enhanced anorexigenic impact on the central nervous system that 
controls nutrient uptake compared to human insulin.   
 
The design of this crossover study allowed a statistical exploration of the relationships 
between changes in the measured variables using structural equation modeling. The 
mathematical model which was developed confirms known physiological 
relationships between food intake, weight and leptin, and between weight and fat free 
mass.  The negative relationship between ghrelin and fat free mass also confirms 
previous studies (24,25). A negative relationship between pancreatic polypeptide and 
fat free mass, has not previously been reported.   
A limitation of the study is that it was an open label design and the fact that test  
 
subjects knew they were on insulin detemir, which has been widely advertised to 
 
 cause less weight gain, might be a confounding factor. 
 
In conclusion, this study shows that a relative reduction in weight gain associated with 
insulin detemir therapy versus NPH insulin is due to a reduction in calorie 
consumption. This effect might be mediated by a direct effect on the brain or by an 
indirect effect on satiety due to the hepatoselective effect of insulin detemir 
modulating orexigenic and anorexigenic hormones. 
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Figure legends 
Figure 1. A: Changes in body weight after 16 weeks of treatment. B: Change in 
energy intake after 16 weeks. C: Change in total energy expenditure after 16 weeks. 
(□ NPH insulin, ■ Insulin detemir) 
 
Figure 2. Mathematical model showing the relationships between changes in 
measured variables. +indicates a significant positive relationship and – indicates a 
significant negative relationship. 
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  NPH insulin Insulin detemir P values 
Weight change over 16 weeks (kg) 1.7±0.52 -0.69±0.39 <0.001 
Fat mass change over 16 weeks (kg) 0.42±0.380 0.16±0.45 0.562 
Fat free mass change over 16 weeks (kg) 1.26±0.31 -0.9±0.25 <0.001 
Energy intake (kcal/day) 2181±122.1 2018±109.4 0.02 
Carbohydrate (gm/day) 237.43±15.02 225.2±15.69 0.203 
Fat (gm/day) 82.59±5.3 69.04±4.45 0.006 
Protein (gm/day) 85.11±5.57 76.6±4.11 0.01 
Calorie intake during unlimited meal (kcal) 871±74.6 823±85.5 0.523 
Total EE (kcal/day) 3233±236.9 3074±301.5 0.334 
Resting EE (kcal/day) 2034±78.6 1932±94.5 0.312 
Resting EE (kcal/day/kg) 24.4±0.99 23.6±1.21 0.522 
Activity EE (kcal/day) 542.7±61.4 588.5±76.4 0.566 
Diet induced thermogenesis (kcal/day) 74.2±7.22 73±7.4 0.777 
HbA1c (%) 7.5±0.26 7.8±0.23 0.061 
Hypoglycaemic episodes  4.9±1.53 4.6±1.58 0.586 
 
Table 1: Weight changes, energy expenditure, energy intake and hypoglycaemic 
episodes during and at the end of treatment periods with insulin detemir and NPH 
insulin 
  
 
Table 2: Fasting hormone concentrations and postprandial hormone AUCs following 
treatment with insulin detemir and NPH insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NPH insulin Insulin detemir P values 
Adiponectin (ng/ml) 13650.2±1749.8 13680.4±1620. 0.953 
Leptin (ng/ml) 10.83±1.99 9.45±1.59 0.039 
Resistin (ng/ml) 9.46±0.90 11.83±2.05 0.047 
IGF-1 (ng/ml) 182.02±21.85 193.01±20.88 0.307 
GLP-1 (pmol/l) 8.18±0.3 8.8±0.41 0.390 
Ghrelin AUC (pg/ml.min) 528.39±19.52 610.92±30.2 0.002 
PYY AUC (pg/ml.min) 135.2±15.1 139.8±14.4 0.432 
Pancreatic polypeptide AUC (pg/ml.min) 777.1±16.3 813.4±16.9 0.001 
